Recent developments to share with you

Kangchuanji Honored as a 2021 Nanjing Gazelle Enterprise

2022-09-12


The "2021 Nanjing Unicorn and Gazelle Enterprise Conference" was held on June 23 in the Jiangning Economic and Technological Development Zone, Nanjing. At the conference, the Jingzhun Research Institute, which continuously studies the development of highgrowth enterprises in Nanjing, released the "2021 White Paper on the Development of Unicorns and Gazelle Enterprises in Nanjing" and presented awards to representatives of unicorn enterprises, cultivated unicorns, and gazelle enterprises. Our company was honored as a 2021 Nanjing Gazelle Enterprise.

Gazelle enterprises are innovative companies that have successfully crossed the "death valley" of startup, gained market recognition for their business model, and entered a phase of high growth. Unicorns and gazelle enterprises have become key indicators of a region's innovation and development vitality, and are often seen as "rising stars" in the new economy.

Keywords:

Related information

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Good News | Kangchuanji Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets Have Been Approved for Market Launch

According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets manufactured by Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.

2026-06-29

A Strong Start to the New Year – Kangchuanji Achieves Multiple Approvals

The new year begins with a wave of good news. Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. has made an excellent start, backed by professional expertise. According to NMPA drug approval information, the following products have been approved for marketing or have passed consistency evaluation: Famotidine Injection (2ml:20mg), Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (2.5/1000mg and 5/1000mg), Isosorbide Dinitrate Tablets (5mg), Vitamin B6 Injection (100mg/ml), Cefdinir Granules (50mg/0.5g), and Ambroxol and Clenbuterol Oral Solution (1ml: ambroxol hydrochloride 1.5mg and clenbuterol hydrochloride 1μg). Among these, Isosorbide Dinitrate Tablets are the first in China to pass consistency evaluation. As a partner, Kangchuanji provided solid pharmaceutical R&D services, successfully supporting these drugs through the review and approval process.

2026-03-23